NEWS: Novel Spray Package Wins Design Award


GlaxoSmithKline’s (GSK; London) Veramyst/Avamys-brand nasal spray delivery device won a 2008 Medical Design Excellence Award (MDEA) in the Finished Packaging category. The nasal spray device is a prescription medication for treatment of allergic rhinitis and has now been launched in the United States and European markets with further approvals expected over the next couple of months.

Veramyst delivers medication by means of a novel, ergonomically designed, side-actuated delivery device, focusing on ease of use and overcoming patient dissatisfaction with traditional nasal sprays.

“The challenge for the GSK design team was to develop a novel next-generation device that addresses patient dissatisfaction with traditional top-actuated nasal sprays,” says Jim Godfrey, device technology manager of GSK research and development located in Ware, United Kingdom. “We conducted an extensive review of published human-factors literature and determined the key dimensions and operational ranges, from which design concepts were modeled. These concept devices were evaluated by user groups, whose feedback was taken into account when refining and finalizing the design.”

GSK consulted patients, caregivers, and healthcare professionals in the design phase. In addition, market research and three ergonomic studies were conducted during the development of the device, Godfrey says. The first of the three studies verified that the Veramyst side-actuated device nozzle is suitable for use with children as young as 2 years old. The second study demonstrated that patients and third-party caregivers were able to use the device effectively. GSK’s third study sought to determine that the Veramyst device is an improvement on traditional, top-actuated nasal sprays. In terms of promoting both ease of use and comfort during administration, the study verified that the device improved upon the traditional design. It also demonstrated that its patient information leaflet was clear and easy to understand, Godfrey says.

The device requires a minimal number of steps for use, which facilitates user understanding and can be represented easily for the patient in an instruction leaflet. Its ergonomically designed side actuation’s operating forces can be achieved by both children and the elderly, and Veramyst’s shorter nozzle in­creases comfort for patients, especially children, Godfrey says. Its side actuation makes delivery easier for third-party caregivers. The device delivers a low-volume shot weight, which prevents medication from running down the back of the throat.

Veramyst’s flexible seal stopper allows the device to remain primed while the product sits, resulting in fewer operating steps required and less product wastage, Godfrey says. “Traditional top-down nasal sprays may lose their prime when not in use, thus affecting the accuracy of the following dose.”

The MDEA presentation ceremony will take place at 11:00 a.m. on Wednesday, June 4, in conjunction with the MD&M East 2008 Conference and Exposition in New York City’s Javits Convention Center. The ceremony is open to all conference and expo attendees and exhibitors. For more information, visit

No votes yet